AstraZeneca hits another roadblock as it halts its Volrustomig lung cancer trial, finding no survival benefit over standard chemo — adding to a string of recent setbacks across its pipeline. Yet, the company flashes a few bright spots: two late-stage lung cancer trials delivered positive results, and Enhertu and Tagrisso showed strong efficacy in specific cancers. While shares edged up slightly, they remain down for the year — and investors are watching closely as AstraZeneca pivots Volrustomig toward cervical and mesothelioma trials, hoping to turn disappointment into breakthrough.
Listen in comfort: Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn.
Advertise on DNN: advertise@thednn.ai
This is an automated, high-level news summary based on public reporting. Report issues to feedback@thednn.ai.
Podden och tillhörande omslagsbild på den här sidan tillhör
The Daily News Now!. Innehållet i podden är skapat av The Daily News Now! och inte av,
eller tillsammans med, Poddtoppen.
